A detailed history of Royal Bank Of Canada transactions in Hookipa Pharma Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 210,297 shares of HOOK stock, worth $134,590. This represents 0.0% of its overall portfolio holdings.

Number of Shares
210,297
Previous 220,331 4.55%
Holding current value
$134,590
Previous $178,000 16.29%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$0.61 - $0.83 $6,120 - $8,328
-10,034 Reduced 4.55%
210,297 $149,000
Q4 2023

Feb 14, 2024

SELL
$0.42 - $0.86 $83,849 - $171,692
-199,642 Reduced 47.54%
220,331 $178,000
Q3 2023

Nov 14, 2023

BUY
$0.58 - $0.91 $11,349 - $17,806
19,568 Added 4.89%
419,973 $260,000
Q2 2023

Aug 14, 2023

SELL
$0.71 - $1.97 $15,888 - $44,084
-22,378 Reduced 5.29%
400,405 $352,000
Q1 2023

May 15, 2023

BUY
$0.72 - $1.03 $16,181 - $23,148
22,474 Added 5.61%
422,783 $312,000
Q4 2022

Feb 14, 2023

BUY
$0.73 - $1.31 $79,827 - $143,252
109,353 Added 37.58%
400,309 $324,000
Q3 2022

Nov 14, 2022

BUY
$1.27 - $1.87 $35,894 - $52,851
28,263 Added 10.76%
290,956 $390,000
Q2 2022

Aug 15, 2022

BUY
$1.33 - $2.31 $9,057 - $15,731
6,810 Added 2.66%
262,693 $428,000
Q1 2022

May 16, 2022

BUY
$1.26 - $2.52 $113,692 - $227,384
90,232 Added 54.47%
255,883 $584,000
Q4 2021

Feb 14, 2022

BUY
$2.33 - $5.94 $138,073 - $351,998
59,259 Added 55.7%
165,651 $386,000
Q3 2021

Nov 15, 2021

BUY
$5.89 - $9.35 $415,445 - $659,492
70,534 Added 196.7%
106,392 $626,000
Q2 2021

Aug 16, 2021

BUY
$9.16 - $19.51 $328,459 - $699,589
35,858 New
35,858 $329,000

Others Institutions Holding HOOK

About HOOKIPA Pharma Inc.


  • Ticker HOOK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,654,500
  • Market Cap $33.1M
  • Description
  • HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transpl...
More about HOOK
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.